Abstract Number: 837 • 2012 ACR/ARHP Annual Meeting
Response to MMF Therapy for Lupus Nephritis Is Independent of Genetic Variation of Inosine Monophosphate Dehydrogenase
Background/Purpose: The Aspreva Lupus Management Study (ALMS) demonstrated the efficacy of mycophenolate mofetil (MMF-a prodrug of MFA, mycophenolic acid) for both induction and maintenance of…Abstract Number: 838 • 2012 ACR/ARHP Annual Meeting
Association of Urinary and Serum Soluble Fn14 Levels and TWEAK Levels with Lupus Nephritis Disease Activity
Background/Purpose: We have showed that the cytokine TWEAK is a biomarker for lupus nephritis (LN). However, soluble receptors for key immune pathways are also potential…Abstract Number: 839 • 2012 ACR/ARHP Annual Meeting
Urinary Levels of High Mobility Group Box 1 Protein Are Elevated in Patients with Active Lupus Nephritis, and Correlate with Renal Histopathology
Background/Purpose: High mobility group box 1 protein (HMGB-1) had been implicated in the pathogenesis of SLE and potentially lupus nephritis (LN). There is increased expression…Abstract Number: 840 • 2012 ACR/ARHP Annual Meeting
Do Serum Hepcidin 25 Levels Predict SLE Renal or Non-Renal Flares?
Background/Purpose: Biomarkers are needed which can accurately predict systemic lupus erythematosus (SLE) flare, allowing tailoring of immunosuppressive therapy to minimize disease damage and medication toxicity.…Abstract Number: 841 • 2012 ACR/ARHP Annual Meeting
Effect of Partial and Complete Proteinuria Recovery in Lupus Nephritis On Long Term Outcomes
Background/Purpose: The identification of partial proteinuria recovery (PPR) of ≥ 50% allows for the detection of an additional number of patients who improve their proteinuria…Abstract Number: 842 • 2012 ACR/ARHP Annual Meeting
Partial and Complete Recovery From Proteinuria in Lupus Nephritis Patients Receiving Standard of Care Treatment
Background/Purpose: In the majority of trials on lupus, partial proteinuria recovery (PPR) (≥ 50% decrease in the proteinuria level) is a component of the composite…Abstract Number: 843 • 2012 ACR/ARHP Annual Meeting
Interferon Regulatory Factor 5 Associates with Systemic Lupus Erythematosus Through Two Distinct and Independent Effects
Background/Purpose: Powerful evidence suggests that Systemic lupus erythematous (SLE or lupus) autoimmunity is mediated by disregulation of the IRF5-NFκB signaling pathway. The interferon regulatory factor 5…Abstract Number: 844 • 2012 ACR/ARHP Annual Meeting
Toll-Like Receptor 9-Independent and Immune Complex-Independent Interferon-α Production by Neutrophils Upon Netosis in Response to Circulating Chromatin
Background/Purpose: Chromatin (which is composed of DNA and histones) represents a major autoantigen in systemic lupus erythematosus (SLE). Interferon-α (IFN-α) plays an important role in…Abstract Number: 845 • 2012 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus Immune Complexes Upregulate the Expression of CD319 and CD229 On Plasmacytoid Dendritic Cells
Background/Purpose: Patients with SLE have an activated type I interferon (IFN) system due to an ongoing IFN-alpha synthesis by plasmacytoid dendritic cells (pDCs) stimulated by…Abstract Number: 846 • 2012 ACR/ARHP Annual Meeting
Preferential Binding to Elk-1 by SLE-Associated IL10 Risk Allele up-Regulates IL10 Expression
Background/Purpose:The established association between IL10 and multiple autoimmune diseases including SLE and elevated levels of IL-10 in SLE patients correlating with disease activity led us to fine-map…Abstract Number: 847 • 2012 ACR/ARHP Annual Meeting
Enhanced ROCK Activation in Patients with Systemic Lupus Erythematosus
Background/Purpose: The Rho GTPases, Rac and RhoA, play a key role in immune responses by regulating both cytoskeletal reorganization and gene expression. RhoA exerts many…Abstract Number: 848 • 2012 ACR/ARHP Annual Meeting
Targeting Glycosphingolipid Biosynthesis Normalises T Lymphocyte Function in Patients with Systemic Lupus Eyrthematosus
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are characterised by hyperactive T-cells that provide help to auto-reactive B-cells. Underlying this hyperactivity are alterations in the…Abstract Number: 849 • 2012 ACR/ARHP Annual Meeting
The Risk of Cardiovascular Disease in Systemic Sclerosis: A Population-Based Cohort Study
Background/Purpose: Recent studies show that the prevalence of subclinical atherosclerosis is increased in individuals with systemic sclerosis (SSc). An accurate understanding of cardiovascular disease…Abstract Number: 850 • 2012 ACR/ARHP Annual Meeting
Elevation of KL-6 At Early Disease Course Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of morbidity and mortality in patients with systemic sclerosis (SSc). However, only a subset of SSc…Abstract Number: 851 • 2012 ACR/ARHP Annual Meeting
An Evidence-Based Screening Algorithm for Pulmonary Arterial Hypertension in Systemic Sclerosis
Background/Purpose: Pulmonary arterial hypertension (PAH) is a leading cause of mortality and late-stage morbidity in systemic sclerosis (SSc). Current PAH screening recommendations are consensus-based and…